Kapitel 70: Malignes Melanom

Ackerman AB (1985) Malignant melanoma in situ: The flat, curable stage of malignant melanoma. Pathology 17: 298-300


Autier P, Dore JF, Lejeune F et al. (1994) Cutaneous malignant melanoma and exposure to sunlamps or sunbeds: An EORTC multicenter case-control study in Belgium, France and Germany. EORTC Melanoma Cooperative Group. Int J Cancer 58: 809-813

Balch CM, Buzaid AC, Soong SJ et al. (2001a) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19: 3635-3648


Hamilton AL, Eder JP, Pavlick AC et al. (2005) Proteasome inhibition with bortezomib (PS-341): A phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol 23: 6107-6116
Handley WS (1907) The Bunterian Lectures - On the Pathology of Melanotic Growths in Relation to Their Operative Treatment. Lancet 169: 927-933
Hess-Stumpf H, Haberey M, Thierauch KH (2005) PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy. Chembiochem 6: 550-557


